CIMZIA® (certolizumab pegol) Label Change Marks Important Advance for European Women of Childbearing Age With Chronic Rheumatic Disease

BRUSSELS, Jan. 9, 2018 /PRNewswire/ -- European Medicines Agency (EMA) has approved label change for UCB's CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with chronic rheumatic disease, during both pregnancy and breastfeeding Data...